Palopegteriparatide

Palopegteriparatide is a prodrug built on Ascendis Pharma's TransCon ("Transient Conjugation") platform: unmodified PTH(1-34) — the same active fragment as teriparatide — is temporarily bound to a large, inert 40 kDa branched methoxy-PEG carrier via a cleavable linker. In the bloodstream, the linker undergoes slow, predictable, temperature- and pH-driven auto-cleavage, releasing free, fully active PTH(1-34) over time rather than in one sharp injection-driven spike.

This sustained-release design directly addresses the core physiological problem in hypoparathyroidism: PTH is normally secreted continuously, but standard immediate-release PTH(1-34) injections deliver hormone as a short pulse that poorly mimics that tonic signal. By approximating continuous PTH exposure, palopegteriparatide aims to restore calcium, phosphate, and vitamin D regulation without the peaks and troughs of conventional replacement.

The FDA approved palopegteriparatide (brand name Yorvipath) in August 2024 for adults with hypoparathyroidism, describing it as the first and only approved treatment of its kind in the US. It had already received European Commission approval in November 2023, following a positive CHMP opinion, and separate MHRA approval in the UK.

Approval rested on the Phase 3 PaTHway trial, a randomized, placebo-controlled study with a long open-label extension. At 26 weeks, 79% of treated patients met the trial's composite efficacy endpoint versus 5% on placebo, and 93% achieved independence from conventional calcium/active-vitamin-D therapy — a response that was largely sustained through a 182-week extension (86% remained responders).

// PTH1 RECEPTOR ACTIVATION

The PTH(1-34) released from the TransCon carrier binds and activates the PTH1 receptor (PTH1R), a G-protein-coupled receptor expressed most highly in kidney and bone, signaling through adenylyl cyclase/cAMP and IP3/PKC/Ca²⁺ pathways.

// RENAL CALCIUM & PHOSPHATE HANDLING

In the kidney, PTH1R activation increases distal tubular calcium reabsorption and reduces proximal tubular phosphate reabsorption, correcting the hypocalcemia and hyperphosphatemia characteristic of hypoparathyroidism.

// VITAMIN D ACTIVATION

PTH signaling induces CYP27B1 in the renal proximal tubule, driving 1-alpha-hydroxylation of 25(OH)D into active calcitriol — restoring a step in calcium regulation that is otherwise impaired without adequate PTH.

// SUSTAINED VS. PULSATILE EXPOSURE

Because the TransCon linker releases PTH(1-34) gradually rather than as an injection-driven spike, palopegteriparatide more closely approximates the body's normal, continuous PTH tone — the specific design rationale behind its once-daily rather than more frequent dosing, and the basis for reduced reliance on conventional calcium/active vitamin D supplementation observed in trials.

PaTHway (Phase 3): At week 26, 79% of palopegteriparatide-treated patients met the composite efficacy endpoint versus 5% on placebo; 93% achieved independence from conventional calcium/active-vitamin-D therapy. At week 52, 81% met the endpoint and 95% were independent of conventional therapy, with none requiring active vitamin D. In the long-term open-label extension (week 182), 86% remained responders. Adverse events occurred in roughly 82% of patients, mostly mild-to-moderate, with no drug-related withdrawals reported.

The label carries a Warnings and Precautions section (not a boxed warning) noting increased osteosarcoma incidence in PTH-analog rat studies; palopegteriparatide is not recommended in patients with elevated baseline osteosarcoma risk (Paget's disease, unexplained elevated alkaline phosphatase, open epiphyses, prior skeletal radiation, or hereditary predisposition). This mirrors teriparatide's own label history — the FDA removed teriparatide's boxed osteosarcoma warning in 2020 after post-marketing surveillance did not confirm the animal-model risk in humans.

The exact theoretical molecular formula of the intact PEGylated prodrug (as opposed to the well-characterized free PTH(1-34) fragment) came from a single labeling source and was not independently cross-verified — treated here as provisional.